0000899243-23-001517.txt : 20230110
0000899243-23-001517.hdr.sgml : 20230110
20230110191248
ACCESSION NUMBER: 0000899243-23-001517
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230106
FILED AS OF DATE: 20230110
DATE AS OF CHANGE: 20230110
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klee Justin B.
CENTRAL INDEX KEY: 0001898314
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-41199
FILM NUMBER: 23522285
MAIL ADDRESS:
STREET 1: C/O AMYLYX PHARMACEUTICALS, INC.
STREET 2: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001658551
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 464600503
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
BUSINESS PHONE: 617-683-0917
MAIL ADDRESS:
STREET 1: 43 THORNDIKE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02141
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-06
0
0001658551
Amylyx Pharmaceuticals, Inc.
AMLX
0001898314
Klee Justin B.
C/O AMYLYX PHARMACEUTICALS, INC.
43 THORNDIKE STREET
CAMBRIDGE
MA
02141
1
1
0
0
Co-Chief Executive Officer
Common Stock
2023-01-06
4
S
0
4122
36.0789
A
2894463
D
Common Stock
2023-01-06
4
S
0
1846
36.7888
A
2892617
D
Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
/s/ Joshua B. Cohen, as Attorney in Fact
2023-01-10